Interim analysis results from Duravelo-2: Zelenectide pevedotin (zele; BT8009) + pembrolizumab in patients (pts) with previously untreated locally advanced/metastatic urothelial carcinoma (la/mUC).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Yohann Loriot, Felipe Reyes-Cosmelli, Hernan Javier Cutuli, Giuseppe Fornarini, Terence W. Friedlander, Benjamin Garmezy, Alfonso Gómez De Liaño Lista, Nicolas Mainardi, Ignacio Duran, Steffen Rausch, Imanol Martinez Salas, Arlene O. Siefker-Radtke, Wen-Pin Su, Christof Vulsteke, Cong Xu, Leslie R. DeMars, Michael Method, Daniel P. Petrylak
Institutions: Université Paris-Saclay, Institut Gustave Roussy, Fundación Arturo López Pérez, Ospedale Policlinico San Martino, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Sarah Cannon, Universidad de Las Palmas de Gran Canaria, Instituto de Oncología de Rosario, Marqués de Valdecilla University Hospital, Instituto de Investigación Marqués de Valdecilla, Universitätsklinikum Tübingen, Hospital Universitario Fundación Jiménez Díaz, The University of Texas MD Anderson Cancer Center, National Cheng Kung University Hospital, University of Antwerp, AZ Maria Middelares, Bicycle Therapeutics (United Kingdom), Yale University
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162563748
Cites:
Cited by:
Related to: